China Researcher's CCR5 Knockout Babies Shock World Into New Gene Editing Debate
Executive Summary
A devoted researcher or a shrewd business entrepreneur, whatever you call him, He Jiankui seems to have what it takes to draw the spotlight to his cutting edge gene editing technology, so controversial that even his employer has joined calls to denounce him.
You may also be interested in...
China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race
A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.